ARALEN Drug Patent Profile
✉ Email this page to a colleague
When do Aralen patents expire, and what generic alternatives are available?
Aralen is a drug marketed by Sanofi Aventis Us and is included in two NDAs.
The generic ingredient in ARALEN is chloroquine phosphate; primaquine phosphate. There are twenty drug master file entries for this compound. Additional details are available on the chloroquine phosphate; primaquine phosphate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARALEN?
- What are the global sales for ARALEN?
- What is Average Wholesale Price for ARALEN?
Summary for ARALEN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 16 |
| Patent Applications: | 3,565 |
| DailyMed Link: | ARALEN at DailyMed |
Recent Clinical Trials for ARALEN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Liverpool School of Tropical Medicine | Phase 4 |
| Translational Genomics Research Institute | Phase 1 |
| HonorHealth Research Institute | Phase 1 |
US Patents and Regulatory Information for ARALEN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | ARALEN | chloroquine phosphate | TABLET;ORAL | 006002-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ARALEN HYDROCHLORIDE | chloroquine hydrochloride | INJECTABLE;INJECTION | 006002-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE | chloroquine phosphate; primaquine phosphate | TABLET;ORAL | 014860-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
